Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CurisSTU:CUS1 -1.20%55 EV-to-EBIT is 0.03 as of Aug. 22, 2026. GuruFocus rates STU:CUS1 with a GF Score™ of 55/100 and a GF Value™ of €8.10 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 373 Biotechnology companies, Curis ranks better than 97.86% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Curis's Enterprise Value is €-0.21 Mil.
Curis's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €-7.47 Mil. Therefore, Curis's EV-to-EBIT for today is 0.03.
The historical rank and industry rank for Curis's EV-to-EBIT or its related term are showing as below:
STU:CUS1'
s EV-to-EBIT Range Over the Past 10 Years
Min: -46.47 Med: -1.1 Max: 1.1
Current: 0.03
During the past 13 years, the highest EV-to-EBIT of Curis was 1.10. The lowest was -46.47. And the median was -1.10.
STU:CUS1's EV-to-EBIT is ranked better than 97.86% of 373
companies
in the Biotechnology industry
Industry Median: 15.29
vs STU:CUS1: 0.03
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Curis's Enterprise Value for the quarter that ended in Jun. 2026 was €13.65 Mil.
Curis's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis EV-to-EBIT Related Terms
Curis EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Curis's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:CUS1 vs ASBP, VTGN, TOVX: EV-to-EBIT Comparison
For the Biotechnology subindustry, Curis's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Curis's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Curis's EV-to-EBIT falls into.
Curis's current Enterprise Value is €-0.21 Mil.
Curis's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.47 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis (STU:CUS1) has a EV-to-EBIT of 0.03 as of Aug. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Curis and its competitors. According to the industry distribution chart, Curis ranks #8 out of 373 companies in the Biotechnology industry, placing it in the top 2.1%.
Is Curis' EV-to-EBIT too high?
Curis' current EV-to-EBIT is 0.03. The Biotechnology industry median EV-to-EBIT is 15.29. Curis' value of 0.03 is 99.8% below this industry median. Based on the distribution chart, Curis ranks #8 out of 373 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Curis has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Curis' EV-to-EBIT compare to ASBP and VTGN?
According to the Biotechnology industry distribution chart, Curis ranks #8 out of 373 companies for EV-to-EBIT. This places Curis in the top 2% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.29. Curis' value of 0.03 is 99.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.29, based on 373 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curis's current EV-to-EBIT of 0.03 is 99.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Curis and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis's current EV-to-EBIT is 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis stock overvalued right now?
Based on GuruFocus' analysis, Curis (STU:CUS1) is currently considered Possible Value Trap. The stock's GF Value™ is €8.10, compared to a current price of €1.32 — trading 83.7% below its estimated fair value. The current EV-to-EBIT is 0.03 and 99.8% below the Biotechnology industry median of 15.29. Curis' overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Curis (STU:CUS1), the current EV-to-EBIT is 0.03 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Curis (STU:CUS1) Overvalued in 2026?
Based on GuruFocus' analysis, Curis stock appears to be undervalued.
The current stock price of €1.32 is trading 83.7% below its estimated GF Value™ of €8.10.
GuruFocus considers Curis to be Possible Value Trap.
Key valuation signals for STU:CUS1:
EV-to-EBIT: 0.03
GF Value™: €8.10 vs. price of €1.32 (83.7% below fair value)
Industry Position: 99.8% below the Biotechnology median (#8 of 373)
No single metric tells the full story. See the STU:CUS1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
55GF Score
Get the complete analysis for STU:CUS1
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CUS1 has been successfully added to your 
